Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Website: palatin.com

Address:

11 Deer Park Drive, Suite 204, Monmouth Junction, United States

MAKO1992 Sep. 21 at 11:45 AM

$PTN when will these guys have an earnings report?

0 · Reply

ajmrtxl Sep. 18 at 4:49 PM

$PTN 's latest data on SqueezeFinder

0 · Reply

Rollercoaster22 Sep. 17 at 7:41 PM

$PTN Can someone explain if this is good for the stock.

1 · Reply

SportTrade Sep. 17 at 1:58 PM

$PTN Anyone know if the INDs were filed or delayed (again?!). See links to their latest corp prezi posted earlier this week I think and no longer includes the “Q4 2026” IND timing present in the August presentation version (see below) that was there since May earnings press release. Trying to figure out but seems like another delay if the timing for data is now clearly pushed off again per below. I’m a believer in the long term potential and the new preclinical data looks promising but ughh this mgmt is not helping themselves if they trying to rebuild credibility to chronically missing guidance with delay after delay = cash burn and impatient investors when you don’t execute See slide 3: https://palatin.com/wp-content/uploads/2021/09/PTN_Corporate_Presentation-September-2026_Final_Version.pdf May PR: https://palatin.com/press_releases/palatin-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update/ August guidance = yellow September guidnace = blue

4 · Reply

Rollercoaster22 Sep. 17 at 5:52 AM

$PTN GLP1? Did I miss something?

1 · Reply

Kernmantel Sep. 16 at 7:18 PM

$PTN If you sell because you think it's a reversal, then it's destined to be just a shakedown. If you hold because you think it's a shakedown, it's destined to be a reversal. It's all based on karma.

0 · Reply

kc444 Sep. 16 at 4:16 PM

$PTN They only have 1.8 million shares outstanding, big pharma can buy this company with their petty cash. Getting their GLP1 candidate to phase 3 might be the catalyst needed to send this stock soaring! In the meantime we will have a lot of 15-20% swings.

0 · Reply

X001 Sep. 15 at 4:52 PM

$PTN 13% up and next day 16% down . No volume. So quiet as it never happened 😅

0 · Reply

WallStWireAds Sep. 15 at 12:48 PM

$PTN GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach. $RYTM $LLY $VKTX https://www.benzinga.com/content/61786779/glp-1s-transformed-obesity-billions-are-now-moving-rare-diseases-require-different-approach

0 · Reply

Rollercoaster22 Sep. 15 at 6:06 AM

$PTN

0 · Reply

Palatin Technologies Slides: Corporate presentation

Aug 13, 2026, 8:00 AM EDT - 5 weeks ago

Palatin Technologies Slides: Corporate presentation

Thu, 06 Aug 2026 09:40:00 -0400 - 6 weeks ago

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Jun 25, 2026, 8:00 AM EDT - 2 months ago

Palatin Technologies Proxy statement: Proxy filing

2026-06-17T19:30:03.000Z - 3 months ago

Palatin Technologies Is Pursuing the Next Generation of MC4R. ...

May 29, 2026, 7:00 AM EDT - 3 months ago

Palatin Technologies Slides: Corporate presentation

2026-05-18T20:08:48.000Z - 4 months ago

Palatin announces approval of its common stock by Nasdaq

Mon, 18 May 2026 16:00:00 -0400 - 4 months ago

Palatin to Begin Trading on Nasdaq Stock Exchange

2026-05-14T17:24:55.000Z - 4 months ago

Palatin price target lowered to $47.50 from $50 at Alliance Global

May 13, 2026, 11:00 AM EDT - 4 months ago

Palatin Technologies Earnings Call Transcript: Q3 2026

May 13, 2026, 11:00 AM EDT - 4 months ago

Palatin Technologies Earnings release: Q3 2026

May 13, 2026, 11:00 AM EDT - 4 months ago

Palatin Technologies Quarterly report: Q3 2026

Wed, 13 May 2026 07:30:00 -0400 - 4 months ago

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

May 13, 2026, 7:00 AM EDT - 4 months ago

Palatin Technologies Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 6 months ago

Palatin Technologies Slides: Corporate presentation

2026-02-18T14:00:03.000Z - 7 months ago

Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline ...

Feb 17, 2026, 11:00 AM EST - 7 months ago

Palatin Technologies Earnings Call Transcript: Q2 2026

Feb 17, 2026, 11:00 AM EST - 7 months ago

Palatin Technologies Earnings release: Q2 2026

Feb 17, 2026, 11:00 AM EST - 7 months ago

Palatin Technologies Quarterly report: Q2 2026

Tue, 17 Feb 2026 07:30:00 -0500 - 7 months ago

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 13, 2026, 7:00 AM EST - 7 months ago

Palatin Technologies Slides: Corporate presentation

2026-01-12T15:30:03.000Z - 8 months ago

Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)

2025-12-17T16:25:27.000Z - 9 months ago

Palatin Technologies Inc trading resumes

2025-12-17T16:20:21.000Z - 9 months ago

Palatin Technologies Inc trading halted, volatility trading pause

2025-12-13T00:38:01.000Z - 9 months ago

JANUS HENDERSON GROUP PLC Acquires Shares in Palatin Technologies Inc

2025-12-12T10:05:19.000Z - 9 months ago

Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals

RYTM

2025-12-11T07:20:11.000Z - 9 months ago

Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?

2025-12-03T12:05:26.000Z - 9 months ago

Palatin initiated with a Buy at Alliance Global

2025-11-24T15:30:17.000Z - 10 months ago

Biotech Alert: Searches spiking for these stocks today

SMMT

2025-11-21T18:45:19.000Z - 10 months ago

Palatin Technologies Inc trading resumes

2025-11-21T18:35:17.000Z - 10 months ago

Palatin Technologies Inc trading halted, volatility trading pause

2025-11-17T16:25:32.000Z - 10 months ago

Palatin Technologies Inc trading resumes

2025-11-17T16:20:31.000Z - 10 months ago

Palatin Technologies Inc trading halted, volatility trading pause

2025-11-14T14:50:32.000Z - 10 months ago

Palatin Technologies Inc trading resumes

2025-11-14T14:41:20.000Z - 10 months ago

Palatin Technologies Inc trading halted, volatility trading pause

Nov 13, 2025, 11:00 AM EST - 10 months ago

Palatin Technologies Earnings Call Transcript: Q1 2026

Nov 13, 2025, 11:00 AM EST - 10 months ago

Palatin Technologies Quarterly report: Q1 2026

Nov 13, 2025, 11:00 AM EST - 10 months ago

Palatin Technologies Earnings release: Q1 2026

Thu, 13 Nov 2025 07:30:00 -0500 - 10 months ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 12:15 PM EST - 10 months ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Oct 17, 2025, 8:00 AM EDT - 11 months ago

Palatin Technologies Registration statement: Registration Filing

Oct 1, 2025, 8:00 AM EDT - 11 months ago

Palatin Technologies Registration statement: Registration Filing

Oct 1, 2025, 8:00 AM EDT - 11 months ago

Palatin Technologies Registration statement: Registration Filing

Sep 22, 2025, 6:00 PM EDT - 12 months ago

Palatin Technologies Annual report: Q4 2025

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Proxy statement: Proxy Filing

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Proxy statement: Proxy Filing

May 14, 2025, 11:00 AM EDT - 1 year ago

Palatin Technologies Earnings Call Transcript: Q3 2025

May 14, 2025, 11:00 AM EDT - 1 year ago

Palatin Technologies Quarterly report: Q3 2025

May 14, 2025, 11:00 AM EDT - 1 year ago

Palatin Technologies Earnings release: Q3 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

PTNT

2025-05-09T12:36:35.000Z - 1 year ago

Two new option listings and two option delistings on May 9th

GOLD

2025-05-09T11:36:25.000Z - 1 year ago

Palatin presents preclinical data on PL9654 and PL9655 at ARVO

2025-05-08T20:50:06.000Z - 1 year ago

Palatin presents results from Phase 3 PL9643 MELODY-1 trial

2025-05-08T10:34:45.000Z - 1 year ago

Palatin announces transition to OTC Pink following NYSE American notice

May 7, 2025, 8:26 PM EDT - 1 year ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

PTNT

May 7, 2025, 5:20 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

2025-05-07T16:30:16.000Z - 1 year ago

Palatin trading halted, news pending

2025-05-07T12:23:20.000Z - 1 year ago

Palatin expects $11.5M financing to cure NYSE American delisting notice

May 7, 2025, 8:15 AM EDT - 1 year ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 5, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Registration statement: Registration Filing

May 5, 2025, 7:30 AM EDT - 1 year ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025, 7:30 AM EDT - 1 year ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Palatin Appeals NYSE American Notice of Delisting

Apr 10, 2025, 4:01 PM EDT - 1 year ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 7:30 AM EDT - 1 year ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Registration statement: Registration Filing

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 13, 2025, 11:00 AM EST - 1 year ago

Palatin Technologies Earnings Call Transcript: Q2 2025

Feb 13, 2025, 11:00 AM EST - 1 year ago

Palatin Technologies Earnings release: Q2 2025

Feb 13, 2025, 11:00 AM EST - 1 year ago

Palatin Technologies Quarterly report: Q2 2025

Feb 13, 2025, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 10, 2025, 4:00 PM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025, 7:30 AM EST - 1 year ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 1 year ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 1 year ago

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00